Security key
005329107
Adagene Inc. - Ordinary shares, par value USD $0.0001 per share (ADAG)
CUSIP: 005329107
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Ordinary shares, par value USD $0.0001 per share
- Total 13F shares
- 1,957,086
- Total 13F value
- $7,671,396
- Share change
- +208,783
- SEC-reported price per share
- $3.92
- Number of holders
- 24
- Value change
- +$1,211,474
- Number of buys
- 13
- Number of sells
- 9
- Shares outstanding
- 83,843,205
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
24
Top holders
10
ADAG full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Previous quarter: Q4 2025
Adagene Inc. SEC filings
Adagene Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 005329107
Recent filing periods:
Ownership snapshot
Top reported holders of ADAG - Adagene Inc. - Ordinary shares, par value USD $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Vincent C. Smith
Disclosed value leader
Vincent C. Smith
Comparable rows
15/15
Latest evidence
18 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 8.7%
13D/G row: Vincent C. Smith
Showing 1-6 of 15 holder rows.
Quick read
Vincent C. Smith leads the comparable SEC ownership view at 8.7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Vincent C. Smith's linked filing trail.
Comparable ownership
Top 5
Vincent C. Smith
8.7%
WuXi PharmaTech Healthcare Fund I...
7%
Jorey Chernett
5.1%
Panacea Innovation Ltd
3.8%
FIL Ltd
1.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Vincent C. Smith |
13D/G
Smith Vincent C
|
8.7%
|
$9,120,679
5,095,351 shares
|
+$2,258,166 | 31 Dec 2025 |
| WuXi PharmaTech Healthcare Fund I L.P. |
13D/G
|
7%
|
$8,187,161
4,121,815 shares
|
-$1,701,888 | 30 Sep 2025 |
| Jorey Chernett |
13D/G
Chernett Jorey
|
5.1%
|
$7,764,445
2,389,060 shares
|
$0 | 16 Mar 2026 |
| Panacea Innovation Ltd |
13D/G
Panacea Venture Healthcare Fund II, L.P.
|
3.8%
|
$4,469,175
2,250,000 shares
|
-$1,564,211 | 30 Sep 2025 |
| FIL Ltd |
13D/G
FIL Limited
|
1.8%
|
$1,320,902
936,810 shares
|
-$4,450,930 | 31 Mar 2025 |
| FMR LLC |
13D/G
|
0.9%
|
$933,679
473,949 shares
|
$0 | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
24
Shares
1,957,086
Rows available
24
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
17
Q1 2026 holders
24
Holder diff
7
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend